Postcoital bleeding

Postcoital bleeding is vaginal spotting or bleeding that starts during or immediately after sexual intercourse and is unrelated to the menstrual cycle, and it is one of the most frequent gynaecological symptoms seen in primary care.

Most episodes have a benign cause such as cervical ectropion, a cervical polyp or cervicitis, but the symptom matters because it is the presenting complaint in roughly one in nine women with cervical cancer, so assessment requires a speculum examination rather than reassurance alone.

Terminology and classification

• The standard English term is postcoital bleeding, abbreviated PCB, and British and WHO coding also use the narrower label postcoital and contact bleeding for bleeding provoked by intercourse or by instrumentation.
• ICD-10 places the symptom at N93.0, postcoital and contact bleeding, which sits inside the N93 block of other abnormal uterine and vaginal bleeding and is distinct from the residual N93.8 category for other specified causes.
• ICD-11 release 2025-01 assigns GA21.0 for postcoital or contact bleeding inside the nonmenstrual bleeding group, and the code should always be quoted with that release because WHO updates the linearisation on a rolling cycle.
• Interoperability anchors include MONDO:0006490 for the symptom, HPO:0034264 for postcoital vaginal bleeding, MedGen C5676839 and UMLS C5676839, while Wikidata Q48834766 carries the cross-references to the other ontologies.
• Older British and American texts called the red, friable columnar epithelium on the ectocervix a cervical erosion, and the modern term cervical ectropion or ectopy marks a deliberate change from a disease label to a physiological description.
• Postcoital bleeding is recorded as a symptom or clinical finding rather than an independent disease entity, so its classification follows the causative lesion such as cervicitis, a polyp, atrophy or carcinoma rather than the bleeding itself.
• It must be separated from postmenopausal bleeding, which carries a different cancer risk and a different diagnostic pathway, and from intermenstrual bleeding, which is not provoked by intercourse.

History

• Hans Hinselmann described colposcopy in 1925, introducing the magnified in vivo examination of the cervix that later became the standard way to inspect a bleeding or abnormal cervix.
• George Papanicolaou reported the vaginal smear technique in 1928 and published the monograph with Traut in 1943, which turned cervical cytology into a population screening test for the lesions that most often cause postcoital bleeding.
• For much of the twentieth century columnar ectopy was treated as an erosion and cauterised routinely, a practice abandoned once studies showed that the appearance is a normal response to oestrogen and that ablation does not lower cancer risk.
• From the late 1970s Harald zur Hausen and colleagues argued that human papillomavirus causes cervical cancer, they cloned HPV16 in 1983 and HPV18 in 1984, and zur Hausen received the Nobel Prize in 2008 for this work.
• The first prophylactic vaccine, Gardasil, was licensed by the United States Food and Drug Administration in 2006, and Cervarix followed in 2009, which shifted the emphasis of postcoital bleeding care towards prevention of the causal infection.
• England moved cervical screening to HPV primary testing in 2019, and WHO launched its 2020 elimination strategy with the 90-70-90 targets, both of which changed how a young woman with postcoital bleeding is triaged.

Epidemiology

• A 2014 systematic review estimated that postcoital bleeding affects between 0.7 and 9.0 percent of menstruating women, a range that reflects differences in definition, recall and the age structure of the populations studied.
• British primary care guidance puts the lifetime experience at about one woman in ten, and Scottish gynaecology guidance notes that roughly 13 percent of women aged 20 to 24 report the symptom in any given year.
• The absolute risk of cervical cancer after postcoital bleeding rises with age, from about 1 in 44,000 at 20 to 24 years to 1 in 5,600 at 25 to 34, 1 in 2,800 at 35 to 44 and 1 in 2,400 at 45 to 54 years.
• When colposcopy and biopsy are performed, cervical intraepithelial neoplasia is found in 7 to 10 percent of women with postcoital bleeding and invasive cervical, vaginal or endometrial cancer in less than 1 percent.
• Postcoital bleeding is the presenting complaint in about 11 percent of women with cervical cancer, and affected women are often diagnosed at a higher stage than women whose cancer is found by screening.
• Global burden remains large, with GLOBOCAN estimating about 604,000 new cervical cancer cases and 342,000 deaths in 2020, most of them in low and middle income countries where screening coverage is incomplete.
• Benign causes dominate the case mix, since cervical polyps are found in about 4 percent of gynaecological patients and are most common in multiparous women in their forties and fifties, while cervical ectropion is frequent during pregnancy and oral contraceptive use.
• Named surveillance sources include the NHS cervical screening programme, which publishes annual coverage and cytology outcomes, GLOBOCAN for national incidence and mortality, and a 2017 Taiwanese national health insurance cohort that examined comorbidities among women with the symptom.

Pathophysiology

• Cervical ectropion exposes the single layer of mucus-secreting columnar cells to the vaginal environment, and this epithelium is friable and bleeds readily when the cervix is rubbed during intercourse.
• Cervical polyps are benign overgrowths of endocervical stroma covered by epithelium with a rich vascular supply, and their thin-walled vessels rupture when the polyp is traumatised.
• Infective cervicitis caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, bacterial vaginosis or Mycoplasma genitalium produces a friable inflamed mucosa that bleeds on contact.
• Hypo-oestrogenic vaginal and cervical atrophy thins the epithelium and depletes glycogen, so the tissue loses its protective layers and becomes petechial and easily traumatised, which is the dominant mechanism after menopause.
• Cervical and endometrial carcinomas replace normal epithelium with fragile tumour tissue and abnormal neovascularisation, and the friable surface of an exophytic lesion bleeds with minimal mechanical contact.
• Trauma from intercourse, a foreign body, an intrauterine device or genital surgery can breach the mucosa directly, and anticoagulant or antiplatelet therapy amplifies bleeding from even trivial lesions.

Clinical features

• Most women describe light postcoital spotting that stains toilet paper or underwear, but frank bleeding, clots or bleeding that continues for hours suggest a larger or more vascular lesion.
• Associated vaginal discharge, dyspareunia, pelvic pain or postcoital pain point towards infection, atrophy or a structural lesion rather than a purely mechanical cause.
• In a postmenopausal woman the same symptom raises the probability of atrophic vaginitis and endometrial or cervical cancer, so age is the single most useful discriminator in the initial consultation.
• During pregnancy and with combined oral contraceptives the high oestrogen state enlarges the ectropion, and an intrauterine device can produce contact bleeding through local endometrial irritation.
• Named complications include iron deficiency anaemia from repeated loss, ascending pelvic inflammatory disease after untreated cervicitis, missed cervical or endometrial cancer, and substantial anxiety about malignancy.
• Red flags that mandate urgent assessment are a visible cervical lesion, persistent bleeding over four weeks, bleeding in a woman aged 45 or over, positive HPV testing, unexplained weight loss or a family history of gynaecological cancer.

Diagnosis

• Assessment begins with a focused history covering timing, amount, provocation, contraception, menopausal status, previous cytology and HPV results, and then proceeds to a speculum examination of the cervix and vagina.
• A speculum examination is the pivotal step because most cervical cancers are visible, and a previous normal smear is not a reason to delay referral when the cervix looks abnormal or bleeding persists.
• Cervical cytology and high-risk HPV testing are performed in women who are due for screening, and a positive HPV test or abnormal cytology leads to colposcopy with directed biopsy of any acetowhite or vascular lesion.
• Nucleic acid amplification tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium are taken when discharge or cervicitis is present, because treating infection resolves the bleeding and prevents pelvic inflammatory disease.
• A pregnancy test is routine in women of reproductive age, and transvaginal ultrasound is used to assess the uterus, endometrial thickness and adnexa when the cervix is normal or symptoms suggest upper tract disease.
• In postmenopausal bleeding an endometrial thickness above 4 millimetres on transvaginal ultrasound triggers endometrial sampling, usually by Pipelle biopsy or hysteroscopy, because atrophy alone does not exclude carcinoma.
• The core differential includes cervical cancer, endometrial cancer, infective cervicitis, cervical polyp, vaginal atrophy, vaginal trauma, a bleeding disorder and anticoagulant use, each distinguished by examination, imaging or laboratory testing.
• NICE guideline NG12, first published in 2015 and updated since, and the NHS cervical screening programme guidance updated in 2023 both direct urgent referral within two weeks when the cervix looks suspicious, regardless of age or smear history.

Management

• Management is cause-directed, so the first decision after examination is whether the bleeding arises from a visible cervical lesion, an infection, atrophy, a polyp or the uterine cavity.
• Cervical polyps are removed by twisting or electrosurgical excision at the time of speculum examination, and the specimen is sent for histology because a small proportion harbour malignancy.
• Asymptomatic cervical ectropion needs no treatment, and when discharge or bleeding is troublesome it can be managed by ablation or excision after negative cytology and HPV testing have excluded neoplasia.
• Presumed cervicitis is treated empirically according to the 2021 CDC sexually transmitted infection guidelines with ceftriaxone 500 mg intramuscularly as a single dose plus doxycycline 100 mg orally twice daily for seven days.
• Atrophic bleeding responds to vaginal oestradiol cream or tablets, and non-hormonal moisturisers are used when oestrogen is contraindicated, with reassessment if bleeding persists beyond four weeks.
• Cervical cancer is staged by the 2018 FIGO system and treated by conisation, radical hysterectomy or chemoradiotherapy according to stage, while endometrial cancer is treated by hysterectomy with bilateral salpingo-oophorectomy and staging.
• Prognosis depends on the cause, since about 60 percent of unexplained episodes resolve within six months, whereas five-year relative survival for cervical cancer is about 67 percent overall and falls sharply with advanced stage.
• Prevention combines HPV vaccination of girls before exposure, regular cervical screening from the recommended age, condom use and prompt treatment of cervicitis, all of which reduce the lesions that present as postcoital bleeding.

Research and controversies

• A 2019 updated meta-analysis of 14 high-income countries found that HPV prevalence fell by 83 percent among girls aged 13 to 19 and by 66 percent among women aged 20 to 24 within five to eight years of vaccination, which should reduce HPV-driven postcoital bleeding.
• HPV self-sampling, endorsed by WHO in 2021, is being scaled up to reach women who do not attend clinic-based screening, and it may shorten the diagnostic delay in women whose only symptom is postcoital spotting.
• Automated visual evaluation and artificial intelligence assisted colposcopy are under prospective evaluation as ways to improve detection of cervical precancer in low-resource settings where expert colposcopists are scarce.
• Thermal ablation and large-loop excision are being compared in randomised trials for treatment of cervical precancer, because ablation is cheaper and easier to deliver but cannot provide a histological specimen.
• WHO's 2020 elimination strategy set the 90-70-90 targets for vaccination, screening and treatment by 2030, and modelling suggests that reaching them would avert millions of cervical cancer deaths, which is the main long-term route to reducing postcoital bleeding from malignancy.